In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Biomet acquires Interpore for $297.4mm in cash

Executive Summary

Orthopedic device company Biomet is acquiring Interpore International (dba Interpore Cross International; develops, manufactures, and sells spinal surgery products) for about $297.4mm. Biomet will pay $14.50 per share (a 29% premium over market average) in cash, or 4.4 times Interpore's 2003 sales revenue, for all of the company's approximately 20.5mm shares outstanding, fully diluted.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register